Jiangsu Hengrui Medicine Co., Ltd.

In September 2015, we entered into a global collaboration and licensing agreement with Jiangsu Hengrui Medicine Co., Ltd. for the development and commercialization of SHR-1210, an investigational anti–PD-1 monoclonal antibody. Under the agreement, Incyte holds the exclusive development and commercialization rights to SHR-1210 worldwide, with the exception of Mainland China, Hong Kong, Macau, and Taiwan.